Pharmaceutical Manufacturing / CDMOs Static & Contamination Control Solutions

Pharmaceutical Manufacturing & CDMO Applications We Support

• Research & Formulation (R&D) – Undefined electrostatic properties of APIs and excipients, such as Minimum Ignition Energy, create scale-up and material flow risks that surface only after commercial-scale handling begins.
• Incoming Materials & Sourcing – Vials, stoppers, and flexible packaging arrive from suppliers already charged from transport, introducing an invisible contamination vector directly into Grade C and Grade B zones.
• Primary Manufacturing (API Production) – Pneumatic transfer and bulk powder handling generate significant static charge, causing yield-robbing cling, blend segregation, and dust explosion risk.
• Sterile Fill-Finish – Static charge on vials and components inside isolators and RABS attracts viable particles in the seconds before stoppering, compromising sterility assurance.
• Solid Dose Manufacturing & Packaging – High-speed tablet compression, blister lines, and foil webs generate charge that causes misfeeds, jams, and micro-stoppages requiring manual intervention.
• Cleanroom Gowning & Personnel Zones – Synthetic gowning materials and operator movement remain leading contributors to triboelectric charge and particle introduction.
• Environmental & Analytical Instrumentation – Static interferes with balances, particle counters, and automated dispensing systems, throwing off readings and undermining data integrity.
• Labeling, Coating & Final QC – Charged surfaces attract particulates and dust during coating, labeling, and packaging, driving cosmetic defects and batch rejections.
• Distribution, Logistics & Cold Chain – Charged packaging attracts warehouse dust, and cold-chain temperature swings can worsen static-related label detachment during the last mile.
• CDMO Multi-Site & Multi-Client Operations – Decentralized manufacturing across facilities amplifies inconsistent control and audit exposure without a standardized static control architecture.

What Standards Govern Static Control in Pharmaceutical Manufacturing?

Pharmaceutical manufacturers and CDMOs are held to a growing, converging set of regulatory and standards frameworks — and the 2022 revision of EU GMP Annex 1 has become the de facto global baseline for sterile manufacturing through alignment with PIC/S, WHO, and FDA risk-based approaches.

• EU GMP Annex 1 (2022 Revision) – Mandates a documented, holistic Contamination Control Strategy (CCS) built on prevention by design rather than reactive monitoring.
• ICH Q9 (Quality Risk Management) – Global framework for risk-based identification and mitigation of contamination sources, including electrostatic attraction.
• ICH Q10 (Pharmaceutical Quality System) – Requires continual improvement driven by data, reinforcing the need for traceable static and contamination data.
• US FDA CGMP, 21 CFR Parts 210 & 211 – Current Good Manufacturing Practice regulations governing the processing, packing, and holding of drugs and finished pharmaceuticals.
• PIC/S & WHO Guidance – International alignment that has extended Annex 1 principles into a global baseline expectation for sterile manufacturing.
• PDA Technical Report No. 90 – Guidance on Contamination Control Strategy development, governance, and continuous improvement.
• ANSI/ESD S20.20 – Global standard for developing, implementing, and maintaining an ESD control program across industries.
• IEC 61340-5-1 – International standard for protection of electronic devices and sensitive instrumentation from electrostatic phenomena.
• NFPA 77 – Recommended Practice on Static Electricity, addressing fire and dust explosion hazards from uncontrolled charge during powder handling.